{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:36Z","timestamp":1792004376643,"version":"4.4.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,11,17]]},"abstract":"<jats:p>\n            WCK 5222 (cefepime-zidebactam, 2 g\u2009+\u20091g, every 8 h [q8h]) is in clinical development for the treatment of infections caused by carbapenem-resistant and multidrug-resistant (MDR) Gram-negative bacilli. We determined the\n            <jats:italic>in vitro<\/jats:italic>\n            susceptibility of 1,385 clinical isolates of non-carbapenem-susceptible\n            <jats:italic>Enterobacterales<\/jats:italic>\n            , MDR\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            (also non-carbapenem susceptible),\n            <jats:named-content content-type=\"genus-species\">Stenotrophomonas maltophilia<\/jats:named-content>\n            , and\n            <jats:italic>Burkholderia<\/jats:italic>\n            spp.\n          <\/jats:p>","DOI":"10.1128\/aac.01432-20","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T12:57:36Z","timestamp":1600174656000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":66,"title":["<i>In Vitro<\/i>\n            Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems"],"prefix":"10.1128","volume":"64","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"},{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-2701","authenticated-orcid":false,"given":"Meredith A.","family":"Hackel","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Bouchillon","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix893"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00031-19"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix411"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"e_1_3_3_7_2","unstructured":"NIH U.S. National Library of Medicine. Clinicaltrials.gov. https:\/\/clinicaltrials.gov. Accessed 6 January 2020."},{"key":"e_1_3_3_8_2","unstructured":"Baxter Healthcare Corporation. Cefepime package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050817s007lbl.pdf."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw593"},{"key":"e_1_3_3_10_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing, 30th ed. M100. CLSI, Wayne, PA.","edition":"30"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz414"},{"key":"e_1_3_3_12_2","volume-title":"ASM Microbe","author":"Bhagwat SS","year":"2017","unstructured":"Bhagwat SS, Takalkar SS, Chavan RP, Friedland HD, Patel MV. 2017. WCK 5222 [Cefepime (FEP)-WCK 5107 (Zidebactam, ZID)]: unravelling sub-MIC pharmacodynamic (PD) effects employing in vivo dose fractionation studies and translating into MIC-based PK\/PD target for MBL-expressing P aeruginosa (PA), abstr P283. ASM Microbe, 1 to 5 June 2017, New Orleans, LA, USA."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00233-19"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616248114"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01019-15"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2011.00268.x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00072-17"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx050"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8010032"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02529-16"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-19"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01648-19"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz294"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00499-20"},{"key":"e_1_3_3_25_2","volume-title":"IDWeek 2019","author":"Sader HS","year":"2019","unstructured":"Sader HS, Carvalhaes CG, Mendes RE, Castanheira M, Flamm RK. 2019. Comparison of cefepime-zidebactam (WCK 5222), ceftazidime-avibactam, and ceftolozane-tazobactam tested against Gram-negative organisms causing pneumonia in United States hospitals in 2018, poster no. 2214. IDWeek 2019, Washington, DC."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa036"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2015.05.005"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-16"},{"key":"e_1_3_3_29_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. M07-A11. CLSI, Wayne, PA, USA.","edition":"11"},{"key":"e_1_3_3_30_2","volume-title":"ASM Microbe","author":"Traczewski MM","year":"2017","unstructured":"Traczewski MM, Bhagwat SS. 2017. Cefepime-zidebactam (FEP-ZID) or WCK 5222 tier 2 broth microdilution MIC quality control versus E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, A. baumannii NCTC 13304 and E. coli NCTC 13353, poster no. Saturday 284. ASM Microbe, 1 to 5 June 2017, New Orleans, LA, USA."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02146-18"},{"key":"e_1_3_3_32_2","volume-title":"ECCMID 2017","author":"Muller A","year":"2017","unstructured":"Muller A, Bhagwat S, Patel M, Mouton J. 2017. Population pharmacokinetics, Monte Carlo simulations and dosing recommendations of cefepime using 90 minutes infusion, including renal impairment. Poster EP0943. ECCMID 2017, Vienna, Austria."},{"key":"e_1_3_3_33_2","volume-title":"ECCMID 2019","author":"Muller A","year":"2017","unstructured":"Muller A, Mouton J. 2017. Population pharmacokinetics of zidebactam (WCK 5107), a novel beta-lactam enhancer antibiotic, in individuals with various renal functions. Poster P1954. ECCMID 2019, Amsterdam, Netherlands."},{"key":"e_1_3_3_34_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2020. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0 2020. http:\/\/www.eucast.org. Accessed 5 January 2020."},{"key":"e_1_3_3_35_2","unstructured":"U.S. Food and Drug Administration. Antibacterial susceptibility test interpretative criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria. Content current as of 1 January 2020."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01432-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01432-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:38:37Z","timestamp":1645479517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01432-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,11,17]]}},"alternative-id":["10.1128\/AAC.01432-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01432-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"2020-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01432-20"}}